Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 25, 2022

SELL
$12.16 - $19.42 $3,648 - $5,826
-300 Reduced 75.0%
100 $1,000
Q1 2022

Apr 14, 2022

SELL
$14.08 - $27.63 $211,411 - $414,864
-15,015 Reduced 97.41%
400 $7,000
Q4 2021

Jan 18, 2022

BUY
$26.55 - $40.57 $388,028 - $592,930
14,615 Added 1826.88%
15,415 $409,000
Q3 2021

Oct 26, 2021

BUY
$39.27 - $72.94 $23,562 - $43,764
600 Added 300.0%
800 $32,000
Q2 2021

Jul 19, 2021

BUY
$31.29 - $56.64 $2,816 - $5,097
90 Added 81.82%
200 $11,000
Q1 2021

Apr 26, 2021

SELL
$39.71 - $90.58 $11,913 - $27,174
-300 Reduced 73.17%
110 $4,000
Q3 2020

Oct 27, 2020

SELL
$28.06 - $37.16 $5,331 - $7,060
-190 Reduced 31.67%
410 $11,000
Q2 2020

Jul 22, 2020

SELL
$18.5 - $34.34 $29,600 - $54,944
-1,600 Reduced 72.73%
600 $17,000
Q1 2020

May 07, 2020

SELL
$14.88 - $32.78 $75,888 - $167,178
-5,100 Reduced 69.86%
2,200 $43,000
Q4 2019

Feb 06, 2020

BUY
$19.49 - $32.63 $9,745 - $16,315
500 Added 7.35%
7,300 $216,000
Q2 2019

Aug 09, 2019

BUY
$20.48 - $27.76 $2,048 - $2,776
100 Added 1.49%
6,800 $168,000
Q1 2019

May 10, 2019

BUY
$19.43 - $26.41 $66,062 - $89,794
3,400 Added 103.03%
6,700 $163,000
Q4 2018

Feb 05, 2019

BUY
$18.19 - $31.79 $18,190 - $31,790
1,000 Added 43.48%
3,300 $75,000
Q3 2018

Nov 07, 2018

SELL
$27.65 - $38.39 $23,226 - $32,247
-840 Reduced 26.75%
2,300 $73,000
Q2 2018

Aug 10, 2018

SELL
$31.4 - $41.01 $263,760 - $344,484
-8,400 Reduced 72.79%
3,140 $112,000
Q1 2018

May 11, 2018

BUY
$29.84 - $44.08 $122,940 - $181,609
4,120 Added 55.53%
11,540 $382,000
Q4 2017

Jan 17, 2018

BUY
$21.89 - $31.34 $47,479 - $67,976
2,169 Added 41.31%
7,420 $228,000
Q3 2017

Oct 17, 2017

BUY
$15.81 - $24.01 $83,018 - $126,076
5,251
5,251 $126,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.